(secondQuint)Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy.

 This was a Phase 2, open-label, multi-center, sequential dose finding study with up to 6 treatment cohorts receiving chemotherapy with 15 participants per cohort.

 The primary objective of this study was to determine the dose of peginesatide administered every 3 weeks (Q3W) by subcutaneous injection associated with a hemoglobin increase of 1 g/dL in 50% of anemic cancer participants receiving chemotherapy at 9 weeks following the first dose.

.

 Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy@highlight

The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneously administered injections of peginesatide in anemic cancer participants receiving chemotherapy.

